Citation Impact
Citing Papers
A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity
2014
Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer
2012
Autonomic Nerve Development Contributes to Prostate Cancer Progression
2013 StandoutScience
Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer
2014
Breast cancer
2019 Standout
The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer
2014
Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer
2012
Influence of obesity on breast cancer receptor status and prognosis
2009
New insights into the mechanisms of epithelial–mesenchymal transition and implications for cancer
2018 Standout
Simultaneous Targeting of Bladder Tumor Growth, Survival, and Epithelial-to-Mesenchymal Transition with a Novel Therapeutic Combination of Acetazolamide (AZ) and Sulforaphane (SFN)
2015
mTOR Signaling in Growth, Metabolism, and Disease
2017 Standout
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K
2014
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Pyroptosis: mechanisms and diseases
2021 Standout
Growth-induced stress enhances epithelial-mesenchymal transition induced by IL-6 in clear cell renal cell carcinoma via the Akt/GSK-3β/β-catenin signaling pathway
2017
Polypharmacology in Drug Discovery: A Review from Systems Pharmacology Perspective
2016
Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092
2015
Genomic Determinants of PI3K Pathway Inhibitor Response in Cancer
2012
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Targeting ferroptosis as a vulnerability in cancer
2022 Standout
AKT/PKB Signaling: Navigating the Network
2017 Standout
Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells
2018 Standout
The PI3K Pathway in Human Disease
2017 Standout
Current treatment strategies for inhibiting mTOR in cancer
2014
Renal cell carcinoma
2017 Standout
Society of Surgical Oncology–American Society for Radiation Oncology Consensus Guideline on Margins for Breast-Conserving Surgery With Whole-Breast Irradiation in Stages I and II Invasive Breast Cancer
2014
The phosphoinositide 3-kinase pathway and therapy resistance in cancer
2015
The Influence of Socioeconomic Disparities on Breast Cancer Tumor Biology and Prognosis: A Review
2009
Management of glioblastoma: State of the art and future directions
2020 Standout
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
2014 Standout
Molecular Docking: Shifting Paradigms in Drug Discovery
2019 Standout
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Combination therapy in combating cancer
2017 Standout
Cancer treatment and survivorship statistics, 2016
2016 Standout
mTORC1 and ferroptosis: Regulatory mechanisms and therapeutic potential
2021
Breast cancer statistics, 2013
2013 Standout
Cancer treatment and survivorship statistics, 2014
2014 Standout
Beta-Blocker Use Is Associated With Improved Relapse-Free Survival in Patients With Triple-Negative Breast Cancer
2011
Works of Farrell Adkins being referenced
PIK3CA/PTEN Mutations and Akt Activation As Markers of Sensitivity to Allosteric mTOR Inhibitors
2012
Triple-Negative Breast Cancer Is Not a Contraindication for Breast Conservation
2011
Triple-Negative Breast Cancer and Obesity in a Rural Appalachian Population
2008
In vitro effects of pentosan polysulfate against malignant breast cells
2004
Epithelial to mesenchymal transition is associated with rapamycin resistance
2015
Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors
2014